In fiscal year 2020, the Peer Reviewed Cancer Research Program established the Convergent Science Virtual Cancer Center, or CSVCC, focusing on the complex issues associated with cancer research and improving patient outcomes. To meet the intent of congressional language, the CSVCC is dedicated to funding research related to military health and mission readiness, for Service Members, their Families, Veterans, and other military beneficiaries.
In fiscal year 2026, the CDMRP received congressional appropriations to address rare cancers and several rare diseases and conditions with potential to impact Service Members during or after service, or their Family members, impacting military readiness.
Through creation of registries and repositories to increase access to small patient populations and few samples, innovative clinical trial designs that reduce participation burden, and...
The Toxic Exposures Research Program supports research to improve detection of military-relevant toxic exposures and diagnosis of exposure-related illnesses and health outcomes for Service Members, Veterans and their Families.
The Congressionally Directed Medical Research Programs fund research for interventions to predict, prevent and treat Warfighters who exhibit early indicators of suicidal behaviors or suicidal ideation. By addressing service-specific factors impacting the mental health and well-being of Service Members, CDMRP-funded research preserves military readiness and the strength, stability and effectiveness of the U.S. Armed Forces.
Together, CDMRP-funded researchers and their partners at the Department of Veterans Affairs advance research using AI to detect cancer spread and predict recurrence, improving survival for those who served our country and everyone impacted by metastatic disease.
The Breast Cancer Research Program plays a leading role in the fight against breast cancer by funding innovative research that will bring an end to the disease. Female breast cancer accounted for the highest cancer incidence rate for the ten leading cancers among active-duty members of the military between 2018 and 2022.
Innovative research funded by the BCRP contributes to high-impact advances in clinical practice and treatment used within...
Since fiscal year 2011, the Alzheimer’s Research Program received $213 million in congressional appropriations, including $15 million in fiscal year 2025, to support research to transform diagnosis and care for people living with Alzheimer’s disease and related dementias. Research funded by the AZRP supports identification of new biomarkers and risk factors for Alzheimer’s disease and related dementias, including risks associated with...
In fiscal year 2025, the Congressionally Directed Medical Research Programs received $407.5 million in congressional funding to address various cancers with relevance to military health and potential impact to mission readiness.
By focusing on patient-identified needs, the CDMRP cancer programs aim to lower the overall impact of cancer on Service Members, Veterans, Families and the Nation.
Since fiscal year 2007, the Amyotrophic Lateral Sclerosis Research Program received $309.4 million in congressional appropriations, including $40 million in fiscal year 2025, to support research to find new treatments and cures for ALS.
Research funded by the ALSRP led to experimental treatments, new biomarkers, and devices advancing through clinical trials or in development with industry partners.
